Future Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018
|
|
- Tiffany Parker
- 5 years ago
- Views:
Transcription
1 Future Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018
2 Why do pharmaceuticals dominate IBD therapy discussions? Evidence-Based Medicine Strongest evidence is large, blinded, randomized, placebo-controlled clinical trial Hard to blind, randomize, or make placebo for nonpharmaceutical interventions (eg: surgery, diet, THC ) Safety mechanisms make such clinical trials expensive Money Global biopharmaceuticals market to exceed $340 billion by 2023 Improving technology Safety and efficacy of pharmaceuticals rapidly improving
3 IBD Drugs: Current Small Molecules Biologicals Steroids 5 ASA s IMM s Anti-TNF s Anti-Integrins Anti-IL-12/23 Prednisone Solu Medrol Budesonide Sulfasalazine Mesalamine Balsalazide Azathioprine 6-MP Methotrexate Infliximab Adalimumab Certolizumab Golimumab Natalizumab Vedolizumab Ustekinumab
4 IBD Drugs: Current & Future Small Molecules Biologicals Steroids 5 ASA s IMM s Anti-TNF s Anti-Integrins Anti-IL-12/23 Prednisone Solu Medrol Budesonide Jakinibs Tofacitinib Filgotinib Upadacitinib Sulfasalazine Mesalamine Balsalazide Azathioprine 6-MP Methotrexate S1P1 Agonists Ozanimod Etrasimod Infliximab Adalimumab Certolizumab Golimumab Natalizumab Vedolizumab Etrolizumab PF Ustekinumab Briakinumab Brazikumab Guselkumab Risankizumab Mirikizumab
5 How New IBD Drugs Generally Work Block immune cell communication Biologicals: Block signals (cytokines) outside cells from interacting with receptors on cell surface Small Molecules (Jakinibs): Block cell surface receptor signals (kinases) inside cells Block immune cell migration Biologicals: Block receptors (integrins) on circulating cells from recruiting them from blood to tissue Small molecules (S1P1 s): Trap immune cells in lymph nodes
6 Blocking immune cell communication (cytokines) Outside immune cell Biologicals: Anti-TNF, anti-il (infliximab, ustekinumab ) Inside immune cell Small Molecules: Jakinib (tofacitinib ) Olivera P, et al. Gut February 2017 Vol 66 No 2
7 Blocking immune cell migration: Anti-integrins (biologicals)
8 Blocking immune cell migration: S1P1 agonists (small molecules) Activate the S1P1 Receptor, used by lymphocytes to smell their way out of a lymph node
9 Blocking immune cell migration: S1P1 agonists (small molecules) S1P1 receptor gets down-regulated, and lymphocytes get trapped in lymph nodes, so they cannot go to inflamed tissues S1P1 agonist S1P1 agonist
10 Small Molecules versus Biologics Small Molecules Biologicals Pros: Cons: Pros: Cons: Cheap Fast Oral Allergies rare Nonspecific Short half life Specific Long half life Expensive Slow IV or shots Immunogenic
11 Small molecules are much less complex than biologicals
12 Small molecules can be pills
13 Biologicals are proteins. If you eat them, they are food.
14 Estimated Annual Cost for 70 kg Patient prednisone budesonide azathioprine 6-MP MTX (PO) MTX (SQ) sulfasalazine balsalazide Lialda Asacol Delzicol Apriso Pentasa Infliximab* Adalimumab Certolizumab Golimumab Natalizumab* Vedolizumab* Ustekinumab Small molecules are much cheaper than biologicals $120,000 $100,000 $80,000 $60,000 $40,000 $20,000 IBD drugs by price $0 Steroids Immunomodulators 5'ASA's Biologicals Walgreens CVS Target Kmart Costco Kroger Safeway Rite-Aid Walmart HealthWarehouse Blink Health All prices per GoodRx.com or WellRx.com, 9/3/17, and *exclude infusion center costs*
15 Biologic drugs require complex staged culture in sterile bioreactors
16 Small molecules do not
17 Current small molecules are less effective than biologics Crohn s: SONIC Colombel et. al., N Engl J Med 2010;362: c. 15%
18 % of Patients with Benefit (DCDAI>70) % of Patients with Benefit (DCDAI>70) Biologic drug efficacy wanes over time 100% Loss Of Response to Infliximab (ACCENT-I trial, Hanauer, S., Lancet 2002, 359:1541.) 100% Loss Of Response to Adalimumab (CHARM trial, Colombel, J.F., Gastro 2007, 132:52.) 90% 90% 80% 70% Infliximab Dose: 80% 70% Adalimumab Dose: 60% 50% 40% 30% 20% 10% 10 mg/kg (n=112) 5 mg/kg (n=113) 0 mg/kg (n=110) 60% 50% 40% 30% 20% 10% 40 mg weekly (n=157) 40 mg every 2 wks (n=172) none (n=170) 0% 0% Weeks Weeks Crohn s Disease Clinical Trials:
19 Biologic drug efficacy wanes over time: Why? Rapid protein drug clearance? Inflammation gobbles up proteins? Protein is lost in diarrhea? Immune reaction (antibodies) to protein drug? Immune system recognizes protein as foreign Antibodies block or clear drug? Drug target is too specific? Disease mechanism escapes blockade by using a different mechanism?
20 Life finds a way
21
22 Ustekinumab
23 Tofacitinib
24 Tofacitinib safety profile 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Placebo Tofa, 5 mg Tofa, 10 mg Sandborn WJ et. al, N Engl J Med May 4;376(18):
25 Tofacitinib is effective induction therapy for UC Remission at week 8 Mucosal Healing at week 8 Sandborn WJ et. al, N Engl J Med May 4;376(18): Independent but identical phase III induction trials
26 Tofacitinib is effective maintenance therapy for UC Remission at week 52 Mucosal Healing at week 52 Sandborn WJ et. al, N Engl J Med May 4;376(18): Coming this June for UC?
27 Tofacitinib week 4 benefit in Crohn s (phase II) less impressive 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Response Remission Placebo Tofa, 1mg Tofa, 5mg Tofa 15mg Sandborn WJ et. al., Clinical Gastroenterology and Hepatology 2014;12:
28 Filgotinib benefit in Crohn s induction phase II was more impressive 100% 90% Week 10 80% 70% 60% 50% 40% 30% 20% 10% 0% Response (DCDAI of 100) Remission (CDAI < 150) Endoscopic Response (DSES-CD of 50%) Placebo Filgotinib Now recruiting phase III for UC & Crohn s Vermeire S et. al., Lancet Vol 389 January 21, 2017
29 Upadacitinib also worked in Crohn s induction phase II (CELEST) 100% 90% Week 16 80% 70% 60% 50% 40% 30% 20% 10% 0% Response Remission (CDAI < 150) Endoscopic Response (DSES-CD of 50%) Placebo Upa, 3mg Bid Upa, 6mg BID Upa, 12 mg BID Now recruiting phase III for Crohn s, Phase II for UC Upa, 24 mg BID Upa, 24mg QD Sandborn, WB, DDW 2017, abstract 874h, in Gastroenterology, Vol 152 (5), Suppl 1, pp S1308-S1309
30 Ozanimod showed efficacy for UC induction in phase II (TOUCHSTONE) Sandborn WJ et. al., NEJM 2016 May 5;374(18):
31 Ozanimod showed efficacy for UC maintenance in phase II (TOUCHSTONE) Now recruiting phase III for UC, Phase II for Crohn s Sandborn WJ et. al., NEJM 2016 May 5;374(18):
32 Etrasimod showed efficacy for UC induction in phase II (OASIS) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% p=0.004 Clinial + Endoscopic remission Placebo Week 12, UC P<0.001 Clinical remission Etrasimod 2 mg p=0.003 Endoscopic improvement Arena Pharmaceuticals press release, March 19, 2018
33 Entirely new pills for IBD are coming Jakinibs Tofacitinib (Xeljanz) UC only, June 2018 Filgotinib UC & Crohn s, phase III Upadacitinib Crohn s phase III UC phase II S1P1 Agonists Ozanimod UC phase III Crohn s phase II Etrasimod UC phase II data just out Not yet recruiting phase III
34 Newer versions of current biologics are coming Anti-integrins Similar to vedolizumab: Etrolizumab Anti-integrin b7 Blocks a4b7 (like vedolizumab) plus aeb7 PF Anti-addressin MADCAM1 Receptor for integrin a4b7 Anti-IL-23 Similar to ustekinumab: Brazikumab Briakinumab Guselkumab Risankizumab Mirikizumab
35 Clinical decision making: needs predictive biomarkers for guidance
36 Patients with high baseline integrin alpha E expression in colon biopsies responded better to integrin beta 7 blockade than those without.
37 Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Sands et. al., Gastroenterology Jul;153(1): aka Brazikumab, AMG139 Only people with a high blood level of IL-22 responded more to brazikumab than to placebo
38 What is not coming: Mongersen (SMAD7 antisense RNA pill) Phase III trials failed to show anything like phase II successes IL-6 therapies (tocilizumab, etc) Trials canceled due to bowel perforations IL-17 therapies (sekukinumab, brodalumab) Actually made Crohn s worse than placebo did CTLA4 therapy (abatacept) Actually made UC worse than placebo
39 What is new besides drugs? Diet: Autoimmune Protocol (AIP: basically Paleo) diet Specific Carbohydrate Diet (SCD) Partial Enteral Nutrition (PEN) Curcumin Fecal transplant Colonoscopic vs enema vs feeding tube delivery Single vs multiple (pooled) donor(s) Single vs multiple treatments
40 Symptom Severity Score Weeks on AIP Diet HBI (Crohn's: n=7) pmayo (UC: n=6) Calprotectin Weeks on AIP Diet CRP 0 6 Weeks on AIP Diet Albumin 0 6 Weeks on AIP Diet The AIP dietary intervention consisted of a 6-week elimination phase (staged elimination of grains, legumes, nightshades, dairy, eggs, coffee, alcohol, nuts and seeds, refined/processed sugars, oils, and food additives) followed by a 5-week maintenance phase (during which no food group reintroduction was allowed)
41 C re a c tiv e p r o tie n P r e P o s t S C D
42 S im p le E n d o s c o p ic S c o re fo r C ro h n 's d is e a s e P r e P o s t m S C D
43 wpcdai The patients entered clinical remission on 4 12 weeks of EEN and were subsequently maintained on PEN (50% of total calories as polymeric diet, usually Modulen IBD) as a supplementary diet. The route of administration was oral, but if not tolerated, nasogastric feeding was used instead Children with CD who refused EN served as the control group exclusive enteral nutrition (EEN) Months Partial enteral nutrition (PEN) EEN/PEN (n=42) Conventional (n=45)
44 Curcumin: extract of Turmeric Augments mesalamine benefit in mild to moderate UC 3 grams curcumin/day for 1 month Enough to turn stool yellow, alter body odor Blinding thus in question
45 UC Disease Activity Index Curcumin, 150mg, 3x/day (n=29) Placebo (n=33) Weeks
46
47
48 Conclusions: New oral agents for IBS are promising: Jakinibs (tofacitinib, etc.) S1P1 agonists (ozanimod, etc.) New biologic (not oral) agents may have predictive biomarkers: Colon (biopsy) integrin alpha E for etrolizumab Serum (blood) IL-22 for brazikumab Diet remains hard to study Small studies, subjective outcomes No placebo groups/blinding Growing interest in fecal transplant/microbiome Unclear if pooled or single donor is better Need for frequent, repeated transplants how? Colonoscopy unfeasible for frequent use Enemas? Encapsulated stool pills?
Latest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationNew and Emerging Therapies in IBD. Sarah Streett MD, AGAF Clinical Associate Professor of Medicine Stanford University
New and Emerging Therapies in IBD Sarah Streett MD, AGAF Clinical Associate Professor of Medicine Stanford University New and Emerging Therapies in IBD I have no relevant financial disclosures. IBD is
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationSelective leucocyte trafficking inhibitors for treatment of IBD
Selective leucocyte trafficking inhibitors for treatment of IBD Séverine Vermeire MD, PhD Department of Gastroenterology University Hospitals Leuven Belgium Migration of Leucocytes plays a key role in
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationI B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES
I B D m etter than this isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES What types of people have learned how to manage their IBD? Athletes Musicians Firefighters DOCTORS HEROES Artists Presidents Actors
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationResearch Update: Looking for the Answers
Research Update: Looking for the Answers Ted Denson, M.D. Schubert-Martin Inflammatory Bowel Disease Center Research Support: NIH/NIDDK, CCFA, BMRP Figure 2 Approach to Improve Outcomes for our IBD Patients
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationCarefirst.+.V Family of health care plans
Carefirst.+.V Family of health care plans CVS care mark POLICY Document for ENTYVIO The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
More informationWe will discuss: Inflammatory Bowel Diseases. Life With IBD. What Are the Potential Causes of IBD?
We will discuss: Similarities and differences between Crohn s disease (CD) and ulcerative colitis (UC) Risks and benefits of medication, surgery, and integrative treatments in inflammatory bowel diseases
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationTreatment Options. Suresh Pola, MD Kaiser San Diego
Treatment Options Suresh Pola, MD Kaiser San Diego Overview of Treatments! Medications! Diet! Complementary and Alternative Medicines! How to treat Pain Treatment Goals and Target! Goals of Treatment should
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationInflammatory bowel disease: Novel therpaies NZ November 2018
Inflammatory bowel disease: Novel therpaies NZ November 2018 Dr Charlie Lees Consultant Gastroenterologist From the Edinburgh IBD Unit at the Western General Hospital History of treatment for IBD 1950s
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationOf Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationDisease Management Strategies for Moderate to Severe IBD in Adults
Disease Management Strategies for Moderate to Severe IBD in Adults Alyssa Parian, MD Assistant Professor of Medicine Johns Hopkins University April 21, 2016 Outline Overview of IBD Treatments (Benefits/Risks)
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 4-year surveillance (2017) Ulcerative colitis: management (2013) NICE guideline CG166 Appendix A.2: Summary of new evidence from surveillance Patient information
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationManagement of Refractory Crohn s Disease
Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationLooking for Answers. IBD Research March 9, Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic
Looking for Answers IBD Research 2019 March 9, 2019 Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic Disclosures No relevant financial disclosures There is still no cure for IBD Why me? ETIOLOGY
More informationIBD Module 2: Medication and Patient Management. Kami Roake, PharmD Rheumatology & Gastroenterology Pharmacist University of Utah Hospitals & Clinics
IBD Module 2: Medication and Patient Management Kami Roake, PharmD Rheumatology & Gastroenterology Pharmacist University of Utah Hospitals & Clinics Objectives Describe current treatment guidelines and
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationMedical therapies and IBD
Medical therapies and IBD Although there is no cure for IBD, there are many treatment options available. There is no standard treatment for IBD that is effective in all situations or for all patients,
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationMy Child Has Inflammatory Bowel Disease : Why? What now? What s next?
My Child Has Inflammatory Bowel Disease : Why? What now? What s next? George M. Zacur, M.D., M.S. Clinical Assistant Professor Department of Pediatrics and Communicable Diseases Division of Gastroenterology
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationEmerging Therapies in IBD: The Future is Bright October 28 th 2017
Emerging Therapies in IBD: The Future is Bright October 28 th 2017 Nirmal Kaur, MD Director, Inflammatory Bowel Disease Center Division of Gastroenterology Henry Ford Health System Disclosures Research
More informationDietary Options for Inflammatory Bowel Disease
Dietary Options for Inflammatory Bowel Disease Michael J. Rosen, MD, MSCI Schubert-Martin Inflammatory Bowel Disease Center Learning objectives Worldwide rise in the incidence of IBD The relationship between
More information5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
More informationWhat to Eat For a Healthy Gut
What to Eat For a Healthy Gut CHOP IBD Education Day 2018 LINDSEY ALBENBERG, DO NATALIE L. ADLER, RD, CSP, LDN Does diet play a role in the development of IBD? Hou JK et al. American Journal of Gastro
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationVedolizumab: policing leukocyte traffic
Oxford Inflammatory Bowel Disease MasterClass Vedolizumab: policing leukocyte traffic Dr Brian Feagan, London, Canada Vedolizumab : Policing Lymphocyte Traficking Brian G. Feagan Professor of Medicine,
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More informationBest Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease
Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease Mark Lazarev, MD Summary Inflammatory bowel disease (IBD) is a complex disease that is costly both in terms of medical costs
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationCrohn s
Crohn s Disease David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center @IBDMD Disclosures
More informationNutrition as primary therapy in IBD. Dr Clare Donnellan Leeds General Infirmary
Nutrition as primary therapy in IBD Dr Clare Donnellan Leeds General Infirmary Case GB 34 year old female Diagnosed with Crohn s in 2002? Extent Offered steroids or surgery Declined both GB Represented
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationEfficacy of Vedolizumab as Induction Therapy for Inflammatory Bowell Disease in a «real-life» Study. Clinical Study
Efficacy of Vedolizumab as Induction Therapy for Inflammatory Bowell Disease in a «real-life» Study Clinical Study Q. Trefois (1), O. Descamps (2), J-C. Coche (3), M. Schapira (4) 1 Depar t m ent o f H
More informationGarrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor
Garrick Brown, MD Digestive Health Specialists Tacoma Gig Harbor Today s Objectives Define IBD, its potential causes and diagnosis Discuss management and treatment Discuss complementary and alternative
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More information